PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DP23F58338510110846!zanamivir for INHAL — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent SPE2DP22D0009. PoP ended Mar 18, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Glaxosmithkline LLC

Recipient

Mar 18, 2024

PoP end

$542K

Obligated

$542K

Potential

325412

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal

Contract numberSPE2DP23F5833

Also listed asSPE2DP-23-F-5833

Also listed asSPE2DP22D0009-SPE2DP23F5833

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentGlaxosmithkline LLC

CAGE667E9

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2DP22D0009

Place of performanceDURHAM NC

Pricing typeFirm Fixed Price

Extent competedNot Competed

PoP startAug 29, 2023

PoP end (current)Mar 18, 2024

Obligated$542K

Current value$542K

Potential value$542K

8510110846!ZANAMIVIR FOR INHAL is a federal award for Dla Troop Support held by Glaxosmithkline LLC. Estimated value $542K ($542K obligated). Current period of performance ends Mar 18, 2024. Place of performance: DURHAM NC.

Recompete timing

Public

● Past PoP end (886 days ago)

Current PoP ended Mar 18, 2024 (886 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same parent · incumbent

75A50125F61019

FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E

$491K

Aug 30, 2026

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DP23F5833?

SPE2DP23F5833 (8510110846!zanamivir for INHAL) is a Dla Troop Support award with a potential value of $542K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is SPE2DP-23-F-5833?

SPE2DP-23-F-5833 is the dashed form of PIID SPE2DP23F5833 (8510110846!zanamivir for INHAL), held by Glaxosmithkline LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded SPE2DP23F5833?

Dla Troop Support awarded SPE2DP23F5833 to Glaxosmithkline LLC (potential $542K).

Who is the incumbent on SPE2DP23F5833?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Mar 18, 2024.

When does Glaxosmithkline LLC’s SPE2DP23F5833 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 18, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Aug 29, 2023